Patents Examined by Aditi Dutt
  • Patent number: 10947305
    Abstract: The present invention is directed to novel Anti-TNF? antibody binding compounds and methods of using the same. Anti-TNF? antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF? antibody binding compound. The invention further provides the use of an Anti-TNF? antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: March 16, 2021
    Assignee: Full Spectrum Genetics, Inc.
    Inventors: Robert DuBridge, Veronica Juan
  • Patent number: 10920193
    Abstract: Described herein are chemically defined, adherent culture protocols for generating functional motor neurons characteristic of diverse hindbrain and spinal cord regions, with high efficiency.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 16, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ethan Scott Lippmann, Neha Sehgal, Randolph Scott Ashton
  • Patent number: 10914748
    Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using erythrocyte-derived extracellular vesicles (EEV) as a biomarker.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: February 9, 2021
    Assignee: Université Laval
    Inventors: Francesca Cicchetti, Eric Boilard, Steve Lacroix, Isabelle St-Amour
  • Patent number: 10906981
    Abstract: Provided herein are compositions, kits, methods and systems related to administering a structure that crosses the blood brain barrier (BBB) along with a monosaccharide, either simultaneously or consecutively. The structure may be, for example an antibody or fusion antibody that binds to an insulin receptor.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: February 2, 2021
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10899839
    Abstract: Methods for inhibiting degeneration of a neuron, methods of treating a neurological/neurodegenerative disease, methods of modulating the directional growth of a neuron, and methods of interfering with the interaction of Wnt and Ryk are provided herein. Also provided are isolated anti-Ryk antibodies and antibody fragments that specifically bind to a binding domain of Wnt.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: January 26, 2021
    Assignee: Tire Regents of the University of California
    Inventor: Yimin Zou
  • Patent number: 10881694
    Abstract: This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling. The formation of this signaling module is dependent on cholesterol for its formation and provides a mechanistic explanation for the protective effects of cholesterol depleting drugs in several non-neural models of cell death. As such, the formation of the signaling module lends itself as a novel screen for the identification of new drugs and therapeutics which would retard its formation and protect against neuronal injury and death.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 5, 2021
    Inventor: Adil A. Khan
  • Patent number: 10865372
    Abstract: An object is to provide a neuron cultivation device which promptly develops bundles of axons extending from neurons in vitro. A device for cultivating neuron with axon, the device comprising a cultivation plate and a plurality of modules arranged in the cultivation plate. Each of the modules includes at least one of first chambers receivable of cell bodies of neurons at least one of second chambers, and at least one of channels receivable of a bundle of axon extended from the cell bodies. The channels connect the first chambers and the second chambers. Bottom ends of the first chambers, the second chambers and the channels are closed and top ends of the first chambers and the second chambers are open.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 15, 2020
    Assignee: THE FOUNDATION FOR THE PROMOTION OF INDUSTRIAL SCIENCE
    Inventors: Teruo Fujii, Yoshiho Ikeuchi, Shohei Kaneda, Jiro Kawada
  • Patent number: 10653797
    Abstract: Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Also disclosed are methods and compositions for delivering therapeutic compounds to such sites. CAQK-coated nanoparticles containing silencing oligonucleotides provide an alternative to local delivery of therapeutics, which is invasive and can add complications to the injury.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 19, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
  • Patent number: 10570172
    Abstract: Self assembling peptides in combination with infectious and non-infectious proteins as inhibitors and diagnostic tools in transmissible spongiform encephalopathies and amyloid producing neuorodegenerative diseases are described herein.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: February 25, 2020
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventor: Robert M. Hnasko
  • Patent number: 10561742
    Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: February 18, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Ziyuan Guo, Zheng Wu
  • Patent number: 10555913
    Abstract: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 11, 2020
    Assignee: MERCK SERONO SA
    Inventors: H. James Brentzel, Jr., Maria Lopez-Bresnahan, Nazih Ammoury
  • Patent number: 10544213
    Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 28, 2020
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Fabrice Heitz, Fabian Wirth, Tobias Welt
  • Patent number: 10538581
    Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: January 21, 2020
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
  • Patent number: 10517900
    Abstract: This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling. The formation of this signaling module is dependent on cholesterol for its formation and provides a mechanistic explanation for the protective effects of cholesterol depleting drugs in several non-neural models of cell death. As such, the formation of the signaling module lends itself as a novel screen for the identification of new drugs and therapeutics which would retard its formation and protect against neuronal injury and death.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: December 31, 2019
    Inventor: Adil A. Khan
  • Patent number: 10501556
    Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 10, 2019
    Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.
    Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
  • Patent number: 10485807
    Abstract: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: November 26, 2019
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Steven A. Goldman, Fraser Sim
  • Patent number: 10471119
    Abstract: A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 12, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventor: Myeong Ok Kim
  • Patent number: 10441641
    Abstract: A method of treating circadian rhythm disorders includes identifying a subject with a circadian rhythm disorder or at least one symptom of a circadian rhythm disorder and administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of a circadian rhythm disorder.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 15, 2019
    Assignee: REVANCE THERAPEUTICS, INC.
    Inventor: Gary E. Borodic
  • Patent number: 10434122
    Abstract: A method of preparing a transplant site for cellular transplantation in a mammal includes the steps of inserting a foreign body comprising a biomaterial into an internal tissue; and removing the foreign body after the tissue surrounding the foreign body has undergone an inflammatory response but before significant fibrous encapsulation has occurred, leaving a neovascularized lumen suitable to receive transplanted cells or islets.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 8, 2019
    Inventor: A. M. James Shapiro
  • Patent number: 10406182
    Abstract: This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalized stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 10, 2019
    Assignee: Reneuron Limited
    Inventors: Caroline Hicks, John Sinden, Lara Stevanato, Randolph Corteling